GSTM1 and Schnyder corneal dystrophy: The idea for the treatment of SCD was to bind small molecules near the mutation site in such a fashion that it would prevent the insertion of the β-globin chain of Hb containing the Val mutation (the donor site) into the hydrophobic pocket of a second Hb molecule (the acceptor site), thereby inhibiting deoxy-HbS polymerization (Fig. 1).